The Congressional Budget Office estimates the package would add $2.4 trillion to the national deficit over a decade and leave ...

Results for IRAKLIA show noninferiority for Sanofi's on-body delivery system for isatuximab, compared with IV administration.

Ivarmacitinib, also known as oral SHR0302, is not yet approved by the FDA, with trials currently exploring its utility in ...

Structured exercise programs should be a part of the standard of care for colon cancer following adjuvant chemotherapy, ...

Zanubrutinib showed long-term efficacy in patients with chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL ...

Colorectal cancer offered the earliest window into the trend of increased cancer incidence among those younger than age 50.

Inhaled corticosteroid (ICS) use was common among patients with bronchiectasis and was associated with reduced exacerbations ...

In the US, individuals die during pregnancy and the postpartum period at a greater and increasing rate than in any other high ...

Congress in Milan, Ola Landgren, MD, PhD, shares what he is most looking forward to and reflects on key advancements and ongoing challenges in hematology.

Panelists discuss how ADA recommendations emphasize treating diabetes as part of overlapping conditions requiring cardiovascular and kidney protection, moving beyond just glycemic control to ...

David Awad, PharmD, BCOP, says pharmacists play a growing role in managing access, safety, and toxicity for these therapies, ensuring treatments are appropriate and sustainable in real-world oncology ...

In May, the FDA granted significant drug approvals across various therapeutic areas, marking notable progress in expanding treatment options for patients.